Anti-Mouse CD154 – Biotin
Anti-Mouse CD154 – Biotin
Product No.: C2349
- -
- -
Clone MR1 Target CD154 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names CD40L, TRAP, T-BAM, CD40LG, HIGM1, IGM, IMD3, TNFSF5, gp39, hCD40L, CD40 Isotype IgG Applications FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Armenian Hamster Immunogen Activated mouse Th1 clone D1.6 Product Concentration 0.5 mg/ml Formulation This biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829440 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this MR1 antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity Clone MR1 recognizes an epitope on mouse CD154. Antigen Distribution CD154 is expressed on activated CD4+ T cells. Background CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis. Antigen DetailsLigand/Receptor CD40 PubMed NCBI Gene Bank ID UniProt.org Research Area Costimulatory Molecules . Immunology Technical Protocols |
Related Products
- -
- -
Prod No. | Description |
---|---|
C2828 | |
C2829 | |
C2823 | |
C2357 | |
C2350 | |
C2349 | |
C2351 | |
F1195 |
Formats Available
- -
- -
Prod No. | Description |
---|---|
C2357 | |
C2350 | |
C2349 | |
C2351 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.